Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ/CatenaŽ (INN: idebenone) in mutliple indications.

Products & Pipeline

Santhera has a late-stage development pipeline in orphan indications. The lead compound RaxoneŽ/CatenaŽ (INN: idebenone) is being developed in three indications: Leber's Hereditary Optic Neuropathy, Duchenne Muscular Dystrophy, and Primary Progressive Multiple Sclerosis.

Clinical Development Programs

Currently, two clinical studies are evaluating the safety and efficacy of RaxoneŽ/CatenaŽ:
- the DELOS study in Duchenne Muscular Dystrophy
- the IPPoMS study in Primary Progressive Multiple Sclerosis, conducted by the National Institutes of Health.

Latest News

April 08, 2014
Santhera Reports Financial Figures for 2013 and Progress towards Turnaround
---
April 04, 2014
Santhera to Present Financial Figures for 2013 and Outlook at Swiss Biotech Day 2014
---
March 19, 2014
Santhera Receives US Patent for Fipamezole in the Treatment of Neurodegenerative Diseases